OHSU

Clinical Trials

The Harold Schnitzer Diabetes Health Center Research Department is committed to promoting and conducting cutting-edge clinical research. Our goal is to enhance the quality of life of those living with or affected by diabetes.

Our efforts to find a cure for diabetes, and to improve life for people with this condition, are made possible by volunteers who participate in research studies. When you volunteer, you help us answer important questions about diabetes.

If you would like to be considered to participate in any of our research studies below, please call 503 494-4704, complete our Online Application Form, or email DMResearchCenter@ohsu.edu for more information.

 

GRADE Study

Study started on: 5/17/13

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

View the Study Brochure

The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, in collaboration with 37 medical clinics, including Oregon Health & Science University, is conducting the GRADE Study (The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study). GRADE is a clinical trial designed for people living with diabetes.  The goal of the study is to find the best combination drug treatment for diabetes.

You may qualify for this study, if you:

  • Have had type 2 diabetes for less than 10 years
  • Are taking metformin as your only diabetes medication 

If you join GRADE, you will:

  • Come to Oregon Health & Science University for four diabetes medical visits each year for up to 7  years
  • Take metformin plus one of 4 other diabetes medications chosen by chance
  • Receive diabetes treatment, FDA approved medicines and supplies at no cost to you
  • Receive physical exams and lab tests at no cost to you
  • Receive $100 at the end of each year as well as $10 per visit 
The GRADE study is being conducted at Oregon Health & Science University. 

eIRB #9157

 

DIAMOND Study

Currently recruiting patients for this study? Yes
 
Principal Investigator is Andrew Ahmann, MD
 
The OHSU Harold Schnitzer Diabetes Health Center is conducting a research study investigating the value of adding a Continuous Glucose Monitoring System (CGM), and possibly an insulin pump, for persons with diabetes who use multiple daily insulin injections (MDI).
You may be eligible to participate if you:
• Have type 1 or type 2 diabetes
• Are age 25 years or older
• Use at least 3 insulin injections per day
• Have a desire to lower your Hemoglobin A1c (measure of blood sugar control)
 
The study will last up to 7 months for people with type 2 diabetes and up to 13 months for people with type 1 diabetes. All study-related care is provided at no cost to qualified participants including a glucose meter, supplies, and laboratory tests. You will be compensated for participating in the study.

eIRB #11129

 

T1D Exchange Study

Study started on: 8/23/10

Currently recruiting patients for this study? No

Principal Investigator is Andrew Ahmann, MD

Currently, large gaps exist in our knowledge and understanding of the best way to manage type 1 diabetes in children and adults. The overall objective of this study is to improve the care of people with type 1 diabetes through sharing data in a common data repository. This study aims to collect core clinical and laboratory data on persons with type 1 diabetes in order to address important clinical issues, develop new research protocols, and locate participants for future clinical studies.

 

TrialNet Study

TrialNet - Pathway to Prevention

Study started on: 2/13/2009

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

The purpose of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals. At risk individuals are those that have a blood relative with type 1 diabetes.

eIRB #5023


LIXILAN-O Study

A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus (T2DM)

Study started on: 6/13/2014

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD 

The purpose of this study to compare the safety and efficacy of a study drug to two FDA approved drugs. The two FDA approved drugs are Insulin Glargine (Lantus) and Lixisenatide. The study drug is a fixed ratio combination of Insulin glargine and lixisenatide. 

You may be eligible to participate in this trial if you:

  • Have Type 2 Diabetes
  • Are at least 18 years old
  • Have never used insulin
Participation will last 37 weeks with 11 visits to OHSU and 10 phone visits.

eIRB #10497